A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2
60
about 2.3 years
18+
Female only
7 sites in CA, LA, MI +3
About this study
Researchers are testing lorigerlimab, a medication, in people with advanced solid tumors. The trial will last for 852 days and involve approximately 60 participants who are female only. Participants will receive lorigerlimab by IV infusion every 21 days until cancer progresses or unacceptable side effects occur.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Lorigerlimab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
monoclonal antibody
intravenous
Primary: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator
Secondary: Best percent change from baseline in tumor size, Disease control rate (DCR), Frequency and severity of adverse events (AEs), serious AEs (SAEs), immune-related AEs (irAEs), and AEs leading to dose modifications or treatment discontinuation., Median duration of response (DoR) per RECIST 1.1 criteria, Median progression free survival (PFS) per RECIST 1.1 criteria, Percent change from baseline in tumor size
Oncology, Reproductive Health